Report cover image

Necrobiosis Lipoidica - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 40 Pages
SKU # DEL19996226

Description

DelveInsight’s, “Necrobiosis Lipoidica - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Necrobiosis Lipoidica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Necrobiosis Lipoidica Understanding

Necrobiosis Lipoidica: Overview

Necrobiosis lipoidica is a rare granulomatous skin disorder that usually appears in the shin area of the body and is often related to diabetes mellitus. It is an idiopathic dermatological condition. In the beginning, the lesions appear as erythematous circle papules that then evolve to well-demarcated, atrophic, shiny, yellow-brown telangiectasic multiple and bilateral plaques. The plaques develop slowly and rarely the condition ulcerates and become painful. The disease is more prevalent in females as compared to males. The exact cause of necrobiosis lipoidica is still unclear.

""Necrobiosis Lipoidica - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Necrobiosis Lipoidica pipeline landscape is provided which includes the disease overview and Necrobiosis Lipoidica treatment guidelines. The assessment part of the report embraces, in depth Necrobiosis Lipoidica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrobiosis Lipoidica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Necrobiosis Lipoidica R&D. The therapies under development are focused on novel approaches to treat/improve Necrobiosis Lipoidica.
Necrobiosis Lipoidica Emerging Drugs Chapters

This segment of the Necrobiosis Lipoidica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Necrobiosis Lipoidica Emerging Drugs
  • Secukinumab: Novartis
Novartis’ lead drug candidate, Secukinumab is currently being evaluated for the treatment of necrobiosis lipoidica. The drug has demonstrated good efficacy in its phase I trial. It is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor thus, inhibiting the release of pro-inflammatory cytokines and chemokines.

Further product details are provided in the report……..

Necrobiosis Lipoidica: Therapeutic Assessment

This segment of the report provides insights about the different Necrobiosis Lipoidica drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Necrobiosis Lipoidica
There are approx. 5+ key companies which are developing the therapies for Necrobiosis Lipoidica. The companies which have their Necrobiosis Lipoidica drug candidates in the most advanced stage, i.e. phase II include, Novartis.
  • Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Necrobiosis Lipoidica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Necrobiosis Lipoidica: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrobiosis Lipoidica therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrobiosis Lipoidica drugs.

Necrobiosis Lipoidica Report Insights
  • Necrobiosis Lipoidica Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Necrobiosis Lipoidica Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Necrobiosis Lipoidica drugs?
  • How many Necrobiosis Lipoidica drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Necrobiosis Lipoidica?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Necrobiosis Lipoidica therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Necrobiosis Lipoidica and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Novartis
  • Processa Pharmaceuticals
Key Products
  • Secukinumab
  • PCS 499

Table of Contents

40 Pages
Introduction
Executive Summary
Necrobiosis Lipoidica: Overview
● Causes
● Mechanism of Action
● Signs and Symptoms
● Diagnosis
● Disease Management
Pipeline Therapeutics
● Comparative Analysis
Therapeutic Assessment
● Assessment by Product Type
● Assessment by Stage and Product Type
● Assessment by Route of Administration
● Assessment by Stage and Route of Administration
● Assessment by Molecule Type
● Assessment by Stage and Molecule Type
Necrobiosis Lipoidica – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
● Necrobiosis Lipoidica companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Necrobiosis Lipoidica Collaboration Deals
● Company-Company Collaborations (Licensing / Partnering) Analysis
● Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
● Comparative Analysis
Secukinumab: Novartis
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
● Comparative Analysis
Drug Name: Company Name
● Product Description
● Research and Development
● Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
● Comparative Analysis
Necrobiosis Lipoidica Key Companies
Necrobiosis Lipoidica Key Products
Necrobiosis Lipoidica- Unmet Needs
Necrobiosis Lipoidica- Market Drivers and Barriers
Necrobiosis Lipoidica- Future Perspectives and Conclusion
Necrobiosis Lipoidica Analyst Views
Necrobiosis Lipoidica Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us